NX-5948

• CAT Number: I041297
• CAS Number: 2649400-34-8
• Molecular Formula: C42H54N12O5
• Molecular Weight: 806.96
• Purity: ≥95%
• Synonyms: 3-[4-[1-[[1-[6-[[(3S)-2,6-dioxopiperidin-3-yl]carbamoyl]pyridin-3-yl]piperidin-4-yl]methyl]piperidin-4-yl]anilino]-5-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazine-2-carboxamide
• InChI: InChI=1S/C42H54N12O5/c1-50-21-22-54(42(50)59)32-3-2-16-53(26-32)35-24-45-37(38(43)56)39(48-35)46-30-6-4-28(5-7-30)29-14-17-51(18-15-29)25-27-12-19-52(20-13-27)31-8-9-33(44-23-31)40(57)47-34-10-11-36(55)49-41(34)58/h4-9,23-24,27,29,32,34H,2-3,10-22,25-26H2,1H3,(H2,43,56)(H,46,48)(H,47,57)(H,49,55,58)/t32-,34+/m1/s1
• InChIKey: HPTPDBYCFHFWJG-CWTKIQHKSA-N
• SMILES: CN1CCN(C1=O)[C@@H]2CCCN(C2)C3=CN=C(C(=N3)NC4=CC=C(C=C4)C5CCN(CC5)CC6CCN(CC6)C7=CN=C(C=C7)C(=O)N[C@H]8CCC(=O)NC8=O)C(=O)N

NX-5948（Cat No.:I041297）is an investigational small molecule developed by Nurix Therapeutics, designed to target and degrade specific proteins involved in cancer progression. It utilizes a unique approach known as targeted protein degradation, which recruits the body’s own ubiquitin-proteasome system to eliminate proteins that drive tumor growth. By targeting key proteins within cancer cells, NX-5948 aims to inhibit tumor survival and proliferation. Early-stage preclinical data suggests it may be effective in treating cancers driven by certain genetic mutations, offering a promising new therapeutic strategy with the potential for fewer side effects than traditional therapies.